Selected Posters and Abstracts
Treatment Strategies in Treatment-experienced Patients
•[P27] Response to mono-class nucleoside regimen of tenofovir DF + Trizivir in antiretroviral-experienced patients: 48 week results and predictors of response
•[P25] Health-related quality of life and tolerability of patients treated in RESIST
•[P32] Simplification to efavirenz + abacavir/lamivudine (Kivexa) in previously suppressed HIV-infected patients compared with other conventional regimens of 2 nucleosides + efavirenz: 6-months of follow-up
•[P34] Tenofovir plus didanosine backbone in HIV-patients failing HAART
•[P35] Saquinavir in double protease inhibitor regimens boosted with ritonavir (r) – results of the AROMA-cohort: comparison of saquinavir/atazanavir/r versus saquinavir/lopinavir/r
•[P37] Nevirapine twice-daily versus once-daily as a simplification strategy after a successful protease inhibitors-based highly active antiretroviral therapy
•[P38] Atazanavir/ritonavir in combination with nevirapine as a nucleoside-sparing strategy in HIV-infected antiretroviral-experienced subjects (NEVATA study)
•[P39] Efficacy and safety of Telzir™ in HIV patients: results from the Spanish Expanded Access Program (EAP)
•

[P42] Efficacy and safety of lopinavir/r and atazanavir without a nucleoside backbone in antiretroviral therapy experienced HIV-infected subjects

•[P46] A study on the performance of combination of Kaletra® and saquinavir twice-daily regimen on a group of antiretroviral therapy experienced patients
•[P50] Study of changes in CD4 cells count after switching tenofovir to abacavir or TDF and didanosine to ABC+lamivudine in patients with a ddI+TDF containing regimen and viral suppression (Europa study): preliminary analysis
•

[P51] Cost-effectiveness of TMC114 (darunavir)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients

 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada